Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.

On the 12 October the Royal College of Nursing presented a live-stream ceremony of the RCN Nursing Awards, to recognise the incredible work that nurses undertake every day. 

Amongst this year’s finalists was the Early Phase Clinical Trials Unit (EPCTU) nursing team, based out of the Churchill Hospital, and part of the Oxford University Hospitals NHS Foundation Trust. The team went onto win the Cancer Research UK/Royal College of Nursing Excellence in Cancer Research Nursing Award 2021.

Some members of the Early Phase Clinical Trials Unit (EPCTU) nursing teamSome members of the Early Phase Clinical Trials Unit (EPCTU) nursing team

This team has seen impressive results after its introduction of a mental well-being assessment for early phase trial patients to ensure they were receiving effective and holistic care from the start of their treatment. The team continue to get fantastic feedback from patients, who are often undergoing very difficult times as they partake in clinical trials for cancer treatment. 

The implementation of the assessment has led to numerous referrals to counselling and other services and it has improved communication between patients and staff, allowing them to broach subjects that may otherwise have been unaddressed. The team has streamlined its referral systems since introducing the assessment. Patient feedback has been positive and nurses feel well supported to discuss emotional topics with patients who have no other treatment options left.

In addition, the nurses support and implement the important clinical trials that the unit is known for, running approximately 80 every year, and many of which are the first-in-human trials of innovative cancer treatments. 

 The award was received by Rosie Lomas and her team, and recognises the dedication and hard work the EPCTU Nursing Team put into patient care.


The Early Phase Trials Unit was significantly hit by the pandemic – the trials ward was shut and many staff were deployed to acute medical teams. Despite this, the remaining team members found ingenious ways to continue patients on the trial drugs they needed to keep them alive. 

In addition, by integrating palliative care and introducing wellbeing assessments, they provided greater symptom support and pastoral care to the patients during this extremely difficult time. 

Particular credit should go to Caroline Miles for her benevolent leadership of the nursing team, the nurses themselves and the medics and administrative teams who worked tirelessly alongside them. Well done all!

- Prof.  Sarah Blagden, Oxford’s ECMC lead



Similar stories

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Advancing radiotherapy technology through clinical trials

Rob Stepney participated in a radiotherapy clinical trial in Oxford in 2021. He talks about his experience on the trial and accessing a state-of-the-art machine that uses real-time imaging to improve tumour targeting.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS

A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.

University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer

The University of Oxford is pleased to announce commencement of enrollment for the Phase I PanDox study of thermosensitive liposomal doxorubicin triggered by focused ultrasound in patients with pancreatic cancer.

Hidden lung damage from COVID-19 revealed in new study

Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.